Economic Evaluation of Palliative Management versus Peritoneal Dialysis and Hemodialysis for End-Stage Renal Disease: Evidence for Coverage Decisions in Thailand Yot Teerawattananon1 Miranda Mugford2 Viroj Tangcharoensathien1 1Ministry of Public Health, Nonthaburi, Thailand 2University of E

The economic impact of alcohol consumption: A systematic review. Montarat Thavorncharoensap1,2 Yot Teerawattananon1 Jomkwan Yothasamut1 Chanida Lertpitakpong1 Usa Chaikledkaew1,2 1Health Intervention and Technology Assessment Program (HITAP); Ministry of Public Health, Nonthaburi, Thailand 2Depar

Human papillomavirus vaccine introduction in low and middle income countries: guidance on the use of cost-effectiveness models Mark Jit1, Nadia Demarteau2†, Elamin Elbasha3†, Gary Ginsberg4†, Jane Kim5†, Naiyana Praditsitthikorn6†, Edina Sinanovic7† and Raymond Hutubessy8* † Contributed equally 8

Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand Pattara Leelahavarong1*, Yot Teerawattananon1, Pitsaphun Werayingyong1, Chutima Akaleephan2, Nakorn Premsri3, Chawetsan Namwat3, Wiwat Peerapatanapoki

This issue of the HITAP Newsletter offers articles and stories of priority setting in the context of real world examples and practices that relate to the development of a benefits package for UHC. We hope to bring our readers towards a closer understanding of the means with which we can achieve equi

In response to a lack of cost-effective data on screening and early treatment of diabetes and hypertension in resource-limited settings, a model-based economic evaluation was performed on the World Health Organization (WHO)’s Package of Essential Non-communicable (PEN) disease interventions for prim

Abstract Introduction: As part of the development of a system for the screening of refractive error in Thai children, this study describes the accuracy and feasibility of establishing a program conducted by teachers. Objective: To assess the accuracy and feasibility of screening by teachers.

Abstract Background: Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand. There have also been no economic evaluation studies of CHB drug treatments conducted in Thailand yet. I

Pitsaphun Werayingyong, BPharm, MSc1, Nittaya Phanuphak, MD2, Kulkunya Chokephaibulkit, MD3, Sripen Tantivess, BPharm, PhD1, Nareeluk Kullert, BSc4, Kakanang Tosanguan, BPharm1, Rukmanee Butchon, MSc1, Nipunporn Voramongkol, MD4, Sarawut Boonsuk, MD5, Songyot Pilasant, BSc1, Wantanee Kulpeng, BSc1,

Phanthipha Wongwai a, Pritaporn Kingkaew b, Somkiat Asawaphureekorn a, Tharatip Kolatat c aDepartment of Ophthalmology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40000, Thailand bHealth Intervention and Technology Assessment Program (HITAP), Nonthaburi 11000, Thailand cDepartment of Pa